Results

This is a permanent results page for your analyzed data. Please save the link in your browser's address bar.

GEN3VA Reports for these tags

DRUGS_BD2K_LINCS_DCIC_COURSERA

SOFT file
Title / Description Genome-wide gene expression analysis on remote non-infarcted myocardium after treatment with Valsartan in a mouse model of myocardial infarction
Accession GSE68426
Summary To find which genes were significantly modulated by Valsartan in non-infarcted left ventricle, 4 weeks after coronary artery ligation, and to correlate emerging modulated pathways with histology and cardiac magnetic resonance (CMR) imaging. The goal was to validate the estimation of the systolic dysfunction and of the regions preserved by pharmacological treatment performed with a CMR index. Title of the associated submitted paper: Evaluation of left ventricle function by regional fractional area change (RFAC) in a mouse model of myocardial infarction secondary to Valsartan treatment. Abstract: Purpose: Left ventricle (LV) regional fractional area change (RFAC) measured by cardiac magnetic resonance (CMR) allows the non-invasive localization and quantification of the extent of myocardial infarction (MI), and could be applied to assess the effectiveness of pharmacological or regenerative therapies. Here we investigate the ability of RFAC to identify regional dysfunction and discriminate the effect of pharmacological treatment with valsartan, a selective antagonist of angiotensin II type 1 receptor, in a model of MI. Methods: C57BL/6N mice, undergoing coronary artery ligation, were divided into two groups: untreated (MI) or treated with Valsartan (MI+Val). Sham-operated mice were used as a control. Cardiac dimensions and function were assessed at baseline, 24 hours, 1 and 4 weeks post surgery by CMR and echocardiography. At sacrifice histology and whole-genome gene expression profiling were performed. Results: RFAC was able to detect significant differences between treatment groups whereas the global ejection fraction was not. RFAC showed greater loss of contractility in remote non-infarcted myocardium in MI group than in MI+Val group. Consistently, in the same region MI+Val mice showed reduced myocyte hypertrophy, fibroblast proliferation, and fibrosis and modulation of target genes; in addition, left atrium volumes, appendage length and duct contractility were preserved. Conclusion: In this study, RFAC effectively estimated the degree of systolic dysfunction and discriminated the regions preserved by pharmacological treatment. RFAC index is a promising tool to monitor changes in LV contractility and to assess the effectiveness of therapeutic regimens in clinical settings.
Organism Mus musculus
Platform GPL6887
Normalized False
Parsed SOFT file
Metadata
Differential expression method Characteristic Direction
Cutoff 500
Cell_type Myocardium
Drug_id DB00177
Drug_name Valsartan - 4 weeks
Organism Mouse
Visualizations
Principal Component Analysis
Hierarchical clustering
External Links and Downloads
Gene lists Enrichr L1000CDS2 PAEA Crowdsourcing
Up
Down
Combined